ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Dare Bioscience Inc

Dare Bioscience Inc (DARE)

0.436
-0.0186
(-4.09%)
Closed May 26 4:00PM
0.465
0.029
(6.65%)
After Hours: 7:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.465
Bid
0.35
Ask
1.70
Volume
557,042
0.401 Day's Range 0.47
0.27 52 Week Range 1.02
Market Cap
Previous Close
0.4546
Open
0.47
Last Trade Time
Financial Volume
$ 242,428
VWAP
0.435207
Average Volume (3m)
697,019
Shares Outstanding
98,562,344
Dividend Yield
-
PE Ratio
-1.44
Earnings Per Share (EPS)
-0.31
Revenue
2.81M
Net Profit
-30.16M

About Dare Bioscience Inc

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve... Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Dare Bioscience Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DARE. The last closing price for Dare Bioscience was $0.45. Over the last year, Dare Bioscience shares have traded in a share price range of $ 0.27 to $ 1.02.

Dare Bioscience currently has 98,562,344 shares outstanding. The market capitalization of Dare Bioscience is $43.37 million. Dare Bioscience has a price to earnings ratio (PE ratio) of -1.44.

DARE Latest News

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across...

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at...

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it was selected as a spoke for the Investor Catalyst Hub...

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to...

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering...

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.03518.164689462670.42990.630.3777510618490.48428853CS
40.17761.45833333330.2880.630.2812767490.35522153CS
12-0.115-19.82758620690.580.630.286970190.37368562CS
260.13540.90909090910.330.630.276725160.36622921CS
52-0.5278-53.16277195810.99281.020.274689240.45516666CS
156-0.835-64.23076923081.32.510.2718407841.61459808CS
260-0.4177-47.32072051660.88273.850.2714972211.64197854CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

DARE Discussion

View Posts
powerbattles powerbattles 2 weeks ago
$DARE took the starter! Secure $22 million in the non-dilutive & phase 2 and phase 3 coming $$$
👍️0
harry crumb harry crumb 3 weeks ago
Wouldn’t touch this turd with monopoly money until after the r/s, an after the shorting!
👍️0
Awl416 Awl416 4 weeks ago
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
👍️0
willlbone willlbone 1 month ago
Vote on R/S.
👍️0
glenn1919 glenn1919 3 months ago
DARE.................................................https://stockcharts.com/h-sc/ui?s=DARE&p=W&b=5&g=0&id=p86431144783
👍️0
starkd748 starkd748 5 months ago
It's dead lol
👍️0
Monksdream Monksdream 6 months ago
DARE new 52 week low
👍️0
Monksdream Monksdream 8 months ago
DARE new 52 week low
👍️0
Monksdream Monksdream 8 months ago
DARE new 52 week low
👍️0
Monksdream Monksdream 10 months ago
DARE newb52 week low
👍️0
harry crumb harry crumb 1 year ago
Might be a runner in due time
👍️0
nonsequetor nonsequetor 1 year ago
The DARE train has not even left the station... gathering up steam...
👍️0
harry crumb harry crumb 1 year ago
1.00 average, 100k
👍️0
nonsequetor nonsequetor 1 year ago
I hope everyone loaded up Monday...
👍️0
nonsequetor nonsequetor 1 year ago
Monday, Jan 23, is the day...
👍️0
harry crumb harry crumb 1 year ago
Yep agree
👍️0
nonsequetor nonsequetor 1 year ago
If Ovaprene is approved by the FDA, it could be the first monthly non-hormonal contraceptive product for women and a first-in-category option for women seeking a hormone-free, self-administered and monthly birth control method.

https://www.biospace.com/article/releases/dare-bioscience-announces-ide-approval-for-a-single-arm-open-label-pivotal-contraceptive-efficacy-study-of-ovaprene-an-investigational-hormone-free-monthly-intravaginal-contraceptive/
👍️0
nonsequetor nonsequetor 1 year ago
DARE starts revenue soon with its first approved drug, Xaciato and its licensing partner OGN. Q1 or Q2. Milestone payments and double digit royalties.

Additionally, they have up to three products entering Ph3 trials this year: Ovaprene, Sildenafil and HRT-1. Ovaprene for sure is entering Ph3 this summer with NIH and licensing partner $BAYRY.

By 2024, they could have FDA-approved products and $4-$5B market share and exclusivity.
👍️0
nonsequetor nonsequetor 1 year ago
DARE Since Post:
$0.3266
(38.27%)
Then:$0.8534
Now:$1.18

Nice chunk of change so far...
👍️0
harry crumb harry crumb 1 year ago
Mayb, mayb not
👍️0
nonsequetor nonsequetor 1 year ago
Since my call
Jan 03, 2023 9:29 AM

$DARE It has begun...

DARE Since Post:
$0.2566
(30.07%)
Then:$0.8534
Now:$1.11

UM...AH... looks like a winner already...
and it has not even started!

BUT...

I really don't care what negativity others post. I have done my DD, bought low, and will ride the wave to prosperity.

DARE is the real thing, with one of a kind, first in class products, that will turn many heads and make some (who do their own DD) wealthy.

Good fortune to all (except shorts, who bet wrong on this leg up).
👍️0
harry crumb harry crumb 1 year ago
Could be but highly unlikely this becomes a winner
👍️0
nonsequetor nonsequetor 1 year ago
Just a little bit of DD will prove you wrong.
👍️0
harry crumb harry crumb 1 year ago
Dont count on it, this team is not an has not proven anything yet. Could use new management for a change, the stock does note promote a very good company
👍️0
nonsequetor nonsequetor 1 year ago
Hop aboard, this is just the beginning!
👍️0
nonsequetor nonsequetor 1 year ago
DARE up over 30% already this year.
👍️0
nonsequetor nonsequetor 1 year ago
Up 20% in 2 days
👍️0
nonsequetor nonsequetor 1 year ago
UP 10% since yesterday morning.
👍️0
harry crumb harry crumb 1 year ago
This pos needs to be shutdown, what a scam
👍️0
harry crumb harry crumb 2 years ago
Some more news on dare
👍️0
nonsequetor nonsequetor 2 years ago
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

https://finance.yahoo.com/news/dar-bioscience-announces-subject-screening-120000980.html
👍️0
harry crumb harry crumb 2 years ago
Some news an this turd is stagnant, very boring company here
👍️0
harry crumb harry crumb 2 years ago
Looks like this pos is going to its 3 yr low of .75 area. What junk!
👍️0
nonsequetor nonsequetor 2 years ago
Q4 will be interesting
👍️0
nonsequetor nonsequetor 2 years ago
WOW!! Nice EOD catapult!!
👍️0
nonsequetor nonsequetor 2 years ago
Another week... another wait...

ZZZZZZZZZZZZZZZZZZZZZZ
👍️0
MattSav MattSav 2 years ago
Good looking week... Hope everyone is enjoying this move upwards... I know we are waiting on 4th quarter for real numbers but wondering if the sentiment here is good enough to through another 10k on shares lol
👍️0
nonsequetor nonsequetor 2 years ago
YES!
👍️0
MattSav MattSav 2 years ago
So should we be excited that they are doing Financials on a Tuesday?
👍️0
MattSav MattSav 2 years ago
So is the corporate presentation today or what I can't open the damn thing
👍️0
nonsequetor nonsequetor 2 years ago
https://www.sec.gov/Archives/edgar/data/0001401914/000149315222019342/ex3-1.htm
👍️0
MattSav MattSav 2 years ago
Anyone find out how the vote went?
👍️0
kruy kruy 2 years ago
You do realize that all the upfront payments and tiered royalties have to be split with the labs that actually invented and produce these products. DARE is only the middleman. These details are all spelled out in the last SEC annual filing.
The best thing that could happen for us shareholders is that some big company that needs a pipeline will buy out this company and its entire complicated business model. Give me $5 a share and I'm happy. Reality wise, I think we could only get $3-$4 because they would need to come to agreements with all the labs that actually engineered all of the products. Either way, I'd be happy with any buyout because the business model as is could take a long time for DARE to break even or show a profit after splitting royalties with all parties involved.
👍️0
nonsequetor nonsequetor 2 years ago
$$$$ Coming in from the Gates!
https://ih.advfn.com/stock-market/NASDAQ/dare-bioscience-DARE/stock-news/88547783/current-report-filing-8-k
👍️0
nonsequetor nonsequetor 2 years ago
This DARE stock will drive a sane man crazy!
👍️0
harry crumb harry crumb 2 years ago
Employee stock incentive plan goes into effect with dare Bod approval. Always good news to have a employee purchase plan for company stock
👍️0
MattSav MattSav 2 years ago
So im new to this stock... What are the opinions of the stock not getting its approval to increase shares?
👍️0
nonsequetor nonsequetor 2 years ago
Just a few more days...
👍️0
nonsequetor nonsequetor 2 years ago
CLINICAL TRIALS RESULTS JUST POSTED
https://www.clinicaltrials.gov/ct2/show/results/NCT03598088?view=results
👍️0
nonsequetor nonsequetor 2 years ago
👍️0

Your Recent History

Delayed Upgrade Clock